Histone Deacetylase 6 Market Research Report -Pipeline Review, H2 2017

“The Latest Research Report Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

About Histone Deacetylase 6 Market

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 6-Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1339570

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 14 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Genetic Disorders, Toxicology, Dermatology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Breast Cancer, Melanoma, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Alzheimer’s Disease, Autoimmune Disorders, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Lymphoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Colon Tumor, Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Endometrial Cancer, Fallopian Tube Cancer, Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Inflammation, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Multiple Sclerosis, Myelodysplastic Syndrome, Neuroblastoma, Neurodegenerative Diseases, Neurology, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Parkinson’s Disease, Peritoneal Cancer, Polycystic Kidney Disease, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sepsis, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Systemic Lupus Erythematosus and Thyroid Cancer.

View Sample PDF @ https://www.marketresearchreports.biz/reports/1339570/histone-deacetylase-6-protein-phosphatase-1-regulatory-subunit-90-or-hdac6-or-ec-35198-pipeline-review-h2-2017-market-research-reports.pdf

Furthermore, this report also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

– The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

– The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1339570

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Overview 9

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 17

Products under Development by Universities/Institutes 24

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Therapeutics Assessment 26

Assessment by Mechanism of Action 26

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Companies Involved in Therapeutics Development 31

Celgene Corp 31

Chong Kun Dang Pharmaceutical Corp 32

Curis Inc 33

HitGen LTD 33

Kancera AB 34

Karus Therapeutics Ltd 34

Medivir AB 35

Merck & Co Inc 35

Millennium Pharmaceuticals Inc 36

OnKure Inc 37

Quimatryx SL 37

Shuttle Pharmaceuticals LLC 37

Sigma-Tau SpA 38

SK Biopharmaceuticals Co Ltd 38

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Drug Profiles 39

ACY-1083-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ACY-738-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ACY-775-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: